T-DXd/Pertuzumab Combo Earns FDA Approval in Advanced HER2+ Breast Cancer


T-DXd/Pertuzumab Combo Earns FDA Approval in Advanced HER2+ Breast Cancer | Oncology Nursing News
The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast ca...


